ALK-Abello posts 1st-qtr 2015 revenue decline but ups full year forecasts
Denmark-based allergy specialist ALK Abello (ALKB: DC) reported this morning that it has delivered revenue growth in the base business at the upper end of the guidance range for the first quarter of 2015.
Total revenue, including partner income, decreased by 9% (local currencies) to 650 million Danish kroner ($97.7 million), said the world’s largest maker of allergy immunotherapy products, whose shares dipped 2.0% to 103.86 kroner in early trading.
Reported earnings before interest, taxes, depreciation and amortization (EBITDA) were 128 million kroner, up 20.75% from 206 million kroner in the like, year-earlier quarter. Excluding milestones payments and sales royalties, EBITDA before special items increased slightly to 132 million kroner, versus 130 million kroner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze